JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

JNJ

230.63

+2.12%↑

ABT

92.43

+0.79%↑

MDT

83.72

+0.54%↑

A

114.27

-5.32%↓

VEEV

156.08

-4.6%↓

Search

Bausch Health Cos Inc

Fermé

SecteurSoins de santé

5.54 -2.46

Résumé

Variation du prix de l'action

24h

Actuel

Min

5.5

Max

5.72

Chiffres clés

By Trading Economics

Revenu

-295M

-114M

Ventes

158M

2.8B

P/E

Moyenne du Secteur

14.071

60.328

Marge bénéficiaire

-4.006

Employés

20,300

EBITDA

-277M

659M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+27.64% upside

Dividendes

By Dow Jones

Prochains Résultats

29 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-15M

2.2B

Ouverture précédente

8

Clôture précédente

5.54

Sentiment de l'Actualité

By Acuity

22%

78%

61 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Bausch Health Cos Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

24 avr. 2026, 00:00 UTC

Résultats

Renesas Electronics 1Q Net Y68.15B Vs Net Y26.01B

23 avr. 2026, 23:47 UTC

Market Talk

Gold Edges Lower Amid Ongoing Concerns Over Higher Inflation -- Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

23 avr. 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over U.S.-Iran Conflict -- Market Talk

23 avr. 2026, 23:13 UTC

Acquisitions, Fusions, Rachats

Trump on Spirit Airlines: 'I Think We'd Just Buy It' -- Update

23 avr. 2026, 22:33 UTC

Résultats

Intel Shares Jump 20% as AI Agents Drive Big Growth -- WSJ

23 avr. 2026, 22:17 UTC

Résultats

PLS Executed Offtake Agreement With Ronbay

23 avr. 2026, 22:17 UTC

Résultats

PLS Secured Up to A$38.1M in Australia Government ARENA Grant Funding

23 avr. 2026, 22:16 UTC

Résultats

PLS Commences Commissioning of Midstream Demonstration Plant

23 avr. 2026, 22:15 UTC

Résultats

PLS Group Reaffirms FY26 Guidance for All Metrics

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Margin From Operations A$461M at March 31

23 avr. 2026, 22:14 UTC

Résultats

PLS Group 3Q Cash Balance A$1.455 Billion at March 31

23 avr. 2026, 22:13 UTC

Résultats

PLS Group 3Q Unit Operating Cost A$733/Ton CIF, Up 2% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

Correct: PLS Group 3Q Unit Operating Cost A$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:12 UTC

Résultats

PLS Group 3Q Unit Operating Cost US$520/Ton FOB, Down 11% on 2Q

23 avr. 2026, 22:11 UTC

Résultats

PLS Group 3Q Realized Price US$1,867/Ton, Up 61% on 2Q

23 avr. 2026, 22:10 UTC

Résultats

PLS Group 3Q Revenue A$567,000, Up 52% on 2Q

23 avr. 2026, 22:09 UTC

Résultats

PLS Group 3Q Sales 195,700 Tons, Down 16% on 2Q

23 avr. 2026, 22:08 UTC

Résultats

PLS Group 3Q Production 232,400 Tons, Up 12% on 2Q

23 avr. 2026, 22:04 UTC

Résultats

Intel Sales Rise 7% as AI Agents Drive Growth -- WSJ

23 avr. 2026, 21:56 UTC

Market Talk
Résultats

Intel Points to Growing Role of CPUs Amid AI Shifts -- Market Talk

23 avr. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

23 avr. 2026, 21:27 UTC

Résultats

Intel CFO: All Demand Signals Point to Growing Role of CPUs in AI Era

23 avr. 2026, 21:25 UTC

Résultats

Intel CFO Expects Factories to Continue Increasing Supply in 3Q, 4Q, but at More Measured Pace Than Previously Expected

23 avr. 2026, 21:24 UTC

Résultats

SAP Stock Rebounds From Software Slaughter. The Cloud Boosted Europe's Tech Titan. -- Barrons.com

23 avr. 2026, 21:24 UTC

Résultats

Blackstone Stock Falls After Earnings. Private Credit Remains in Focus. -- Barrons.com

23 avr. 2026, 21:21 UTC

Résultats

Intel to Look for Unconventional Way to Boost Manufacturing Capacity Through Musk's Terafab Project, CEO Says

23 avr. 2026, 21:21 UTC

Résultats

Intel CEO: He, Elon Musk Believe Global Semiconductor Supply Isn't Keeping Up With Accelerating Demand

Comparaison

Variation de prix

Bausch Health Cos Inc prévision

Objectif de Prix

By TipRanks

27.64% hausse

Prévisions sur 12 Mois

Moyen 7.25 USD  27.64%

Haut 10 USD

Bas 5 USD

Basé sur 5 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

5 ratings

0

Achat

4

Maintien

1

Vente

Score Technique

By Trading Central

4.63 / 5.35Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

61 / 348Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Bausch Health Cos Inc

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
help-icon Live chat